Sexual dysfunction in the highly active antiretroviral therapy era

AIDS Reviews

Volumn 9, Issue 4, 2007, Pages 237-245

  Collazos, Julio ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Adverse effects; Erectile dysfunction; Highly active antiretroviral therapy; Protease inhibitors; Sexual dysfunction

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; AROMATASE; ATAZANAVIR; BENZODIAZEPINE DERIVATIVE; CYTOCHROME P450; DIURETIC AGENT; ESTRADIOL; GONADOTROPIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; KETOCONAZOLE; LETROZOLE; MEGESTROL; NELFINAVIR; NEUROLEPTIC AGENT; NEVIRAPINE; PHOSPHODIESTERASE V INHIBITOR; PROLACTIN; PROTEINASE INHIBITOR; PSYCHOTROPIC AGENT; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SILDENAFIL; TADALAFIL; TESTOSTERONE; UNINDEXED DRUG; VARDENAFIL;

ANAMNESIS; CAUSAL ATTRIBUTION; COGNITIVE THERAPY; DIAGNOSTIC VALUE; DRUG COMPETITION; DRUG EXPOSURE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPAREUNIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPOGONADISM; INCIDENCE; INFORMATION RETRIEVAL; LIBIDO DISORDER; MEDLINE; ORGASM DISORDER; PATHOGENESIS; PATIENT COMPLIANCE; PENIS PROSTHESIS; PREVALENCE; PRIAPISM; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; SEX DIFFERENCE; SEXUAL DYSFUNCTION; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 38749107765     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Martinez E, Collazos J, Mayo J, Blanco M. Sexual dysfunction with protease inhibitors. Lancet. 1999;353:810-11.
2. Schambelan M, Grunfeld C. Endocrine abnormalities associated with HIV infection and AIDS. In: Broder S, Merigan TC, Bolognesi D, eds. Textbook of AIDS Medicine. Baltimore: Williams and Wilkins; 1994:629-36.
3. Dobs A, Dempsey M, Landeson P, Polk B. Endocrine disorders in men infected with HIV. Am J Med. 1988;84:611-15.
4. Danoff A. Endocrinologic complications of HIV infection. Med Clin North Am. 1996;80:1453-69.
5. Aron D. Endocrine complications of AIDS. Arch Intern Med. 1989;149:330-3.
6. Raffi F, Brisseau J, Planchon B, Remi J, Barrier J, Grolleau J. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS. 1991; 5:729-33.
7. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270:83-90.
8. Trotta M, Ammassari A, Cozzi-Lepri A, et al. Adherence to HAART is better in patients receiving nonnucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. AIDS. 2003;17:1099-102.
9. Meyer-Bahlburg H, Nostlinger C, Exner T, et al. Sexual functioning in HIV+ and HIV- injected drug-using women. J Sex Marital Ther. 1993;19:56-68.
10. Jones M, Klimes I, Catalan J. Psychosexual problems in people with HIV infection: controlled study of gay men and men with hemophilia. AIDS Care. 1994;6:587-93.
11. Lue T, Giuliano F, Montorsi F, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2004;1:6-23.
12. Colebunders R, Smets E, Verdonck K, Dreezen C. Sexual dysfunction with protease inhibitors. Lancet. 1999;353:1802.
13. Patroni A, Castelli F, Compostella S, El-Hamad I, Airoldi M, Carosi G. Sexual dysfunctions in HAART treated HIV+ patients. XIII IAC. Durban, South Africa, July 9-14, 2000 [abstract WePeB4243].
14. Sollima S, Osio M, Muscia F, et al. Protease inhibitors and erectile dysfunction. AIDS. 2001;15:2331-2333.
15. Schrooten W, Colebunders R, Youle M, et al. Sexual dysfunction associated with protease inhibitor-containing HAART. AIDS. 2001;15:1019-23.
16. Collazos J, Martinez E, Mayo J, Ibarra S. Sexual dysfunction in HIV-infected patients treated with HAART. J Acquir Immune Defic Syndr. 2002; 31:322-6.
17. Colson A, Keller M, Sax P, Pettus P, Platt R, Choo P. Male sexual dysfunction associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;30:27-32.
18. Lallemand F, Salhi Y, Linard F, Giami A, Rozenbaum W. Sexual dysfunction in 156 ambulatory HIV-infected men receiving HAART combinations with and without protease inhibitors. J Acquir Immune Defic Syndr. 2002; 30:187-90.
19. Imrie J, Stephenson J, Davis M, Hart G, Davidson O, Williams I. Recent experience of sexual dysfunction is associated with high-risk sexual behaviors - A cross-sectional study of HIV-positive gay men attending a London HIV clinic (SHARP - Sex, health and antiretrovirals project). XlV IAC, Barcelona 2002. [abstract WePeD6396].
20. Trotta M, Ammassari A, Cozzi Lepri A, et al. Sexual dysfunction in HAART-treated persons: prevalence, determinants and relationship with adherence. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, July 13-16, 2003 [abstract 769].
21. Cove J, Petrak J. Factors associated with sexual problems in HIV-positive gay men. Int J STD AIDS. 2004;15:732-6.
22. Florence E, Schrooten W, Dreezen C, et al. Prevalence and factors associated with sexual dysfunction among HIV-positive women in Europe. AIDS Care. 2004;16:550-7.
23. Lamba H, Goldmeier D, Mackie NE, Scullard G. Antiretroviral therapy is associated with sexual dysfunction and with increased serum estradiol levels in men. Int J STD AIDS. 2004;15:234-7.
24. Crum N, Wallace M, Powell T, et al. Prevalence and correlates of erectile dysfunction and hypogonadism among HIV-infected men: A prospective study. 12th CROI. Boston 2005 [abstract 875].
25. Lambert S, Keegan A, Petrak J. Sex and relationships for HIV positive women since HAART: a quantitative study. Sex Transm Infect. 2005; 81:333-7.
26. Ende A, Lo Re V, DiNubile M, Mounzer K. Erectile dysfunction in an urban HIV-positive population. AIDS Pat Care STDS. 2006;20:75-8.
27. Bell C, Richardson D, Wall M, Goldmeier D. HIV-associated female sexual dysfunction - clinical experience and literature review. Int J STD AIDS. 2006;17:706-9.
28. Crum-Cianflone N, Bavaro M, Hale B, et al. Erectile dysfunction and hypogonadism among men with HIV. AIDS Pat Care STDS. 2007;21:9-19.
29. Asboe D, Catalan J, Mandalia S, et al. Sexual dysfunction in HIV-positive men is multifactorial: A study of prevalence and associated factors. AIDS Care. 2007;19:955-65.
30. Feldman H, Goldstein I, Hatzichristou D, Krane R, McKinlay J. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging study. J Urol. 1994;151:54-61.
31. Martin-Morales A, Sánchez-Cruz J, Sáenz de Tejada I, Rodríguez-Vela L, Jiménez-Cruz J, Burgos-Rodríguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiología de la Disfunción Eréctil Masculina Study. J Urol. 2001;166:569-74.
32. Hofbauer L, Heufelder A. Endocrine implications of HIV infection. Medicine. 1996;75:262-78.
33. Tindall B, Forde S, Goldstein D, Ross M, Cooper DA. Sexual dysfunction in advanced HIV disease. AIDS Care. 1994;6:105-7.
34. Collazos J, Martinez E, Mayo J, Ibarra S. Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy. AIDS. 2002;16:934-7.
35. Richardson D, Lamba H, Goldmeier D, Nalabanda A, Harris J. Factors associated with sexual dysfunction in men with HIV infection. Int J STD AIDS. 2006;17:764-7.
36. Schrooten W, Dreezen C, Asboe D, Gordilto M, Schönnesson L, Colebunders R. Sexual dysfunction in people treated with antiretroviral treatment. XIV IAC, Barcelona 2002 [abstract MoPeB3254].
37. Colson A, Sax P, Keller M, Platt R, Choo P. Sexual dysfunction in protease inhibitors recipients. 7th CROI; January 30-February 2, 2000; San Francisco, California [abstract 63].
38. Bernal E, Masia M, Padilla S, Gutierrez F. Unexpected improvement of sexual dysfunction during atazanavir therapy. AIDS. 2005; 19:1440-1.
39. Murri R, Fantoni M, Del Borgo C, et al. Nonnucleoside reverse transcriptase inhibitor-containing regimens are associated with increased satisfaction with sexual life. J Acquir Immune Defic Syndr. 2003;34:532-4.
40. Collazos J, Mayo J, Martínez E, Ibarra S. Association beiween sexual disturbances and sexual hormones with specific antiretroviral drugs. AIDS. 2002;16:1294-5.
41. Colebunders R, Schrooten W, Desmet P, De Roo A, Dreezen C. Prevention of nevirapine-associated rash. Lancet. 2001;357:392-3.
42. Dinsmore W. Treatment of erectile dysfunction. Int J STD AIDS. 2004; 15:215-21.
43. Levine LA. Diagnosis and treatment of erectile dysfunction. Am J Med. 2000;109:3-12S.
44. Wagner G, Sáenz de Tejada I. Update on male erectile dysfunction. Br J Med. 1998;316:678-82.
45. Lue T. Drug Therapy: erectile dysfunction. N Engl J Med. 2000; 342:1802-13.
46. Fitzpatrick R, Frost D, Ikkos G. Survey of psychological disturbance in patients attending a sexually transmitted diseases clinic. Genitourin Med. 1986;62:111-15.
47. Ciesla J, Roberts J. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158:725-30.
48. Catalan J, Meadows J. Sexual dysfunction in gay and bisexual men with HIV infection: evaluation, treatment and implications. AIDS Care. 2000;12:279-86.
49. Hijazi L, Nandwani R, Kell P. Medical management of sexual difficulties in HIV-positive individuals. Int J STD AIDS. 2002;13:587-92.
50. Crum-Cianflone N, Bavaro M, Hale B, et al. Prevalence and risk factors of hypogonadism among HIV-infected men. 13th CROI; February 5-8, 2006; Denver, Colorado [abstract 775].
51. Morales A, Buvat J, Gooren L, et al. Endocrine aspects of sexual dysfunction in men. J Sex Med. 2004;1:69-81.
52. Mikhail N. Does testosterone have a role in erectile function? Am J Med. 2006;119:373-82.
53. Traish A, Guay A. Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence. J Sex Med. 2006;3:382-404.
54. Foresta C, Caretta N, Rossato M, Garolla A, Ferlin A. Role of androgens in erectile function. J Urol. 2004;171:2358-62.
55. Collazos J, Mayo J, Martínez E, Ibarra S. Serum cortisol in HIV-infected patients with and without HAART. AIDS. 2003;17:123-6.
56. Goldmeier D, Scullard G, Kapembwa M, Lamba H, Frize G. Does increased aromatase activity in adipose fibroblasts cause tow sexual desire in patients with HIV lipodystrophy? Sex Transm Infect. 2002;78:64-6.
57. Cohen P. The role of estradiol in the maintenance of secondary hypogonadism in males in erectile dysfunction. Med Hypotheses. 1998;50:331-3.
58. Cohen P. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med Hypotheses. 2001;56:702-8.
59. Srilatha B, Adaikan P. Estrogen and phytoestrogen predispose to erectile dysfunction: do ER-alpha and ER-beta in the cavernosum play a role? Urology. 2004;63:382-6
60. Srilatha B, Adaikan P. Estrogen-androgen crosstalk in the pathophysiology of erectile dysfunction. Asian J Androl. 2003;5:307-13.
61. Adaikan P, Srilatha B. Estrogen-mediated hormonal imbalance precipitates erectile dysfunction. Int J Impot Res. 2003;15:38-43.
62. Colson A, Sax P. Sexual dysfunction and HIV infection. AIDS Clin Care. 2000;12:39-46.
63. Collazos J, Ibarra S, Martínez E, Mayo J. Serum prolactin concentrations in patients infected with HIV. HIV Clin Trials. 2002;3:133-8
64. Ram S, Acharya S, Fernando J, Anderson N, Gama R. Serum prolactin in HIV infection. Clin Lab. 2004;50:617-20.
65. Daniell H. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377-84.
66. Bruckert E, Giral P, Heshmati H, Turpin G. Men treated with hypolipidemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther. 1996;21:89-94.
67. Yang Y, Ikezoe T, Takeuchi T, et al. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci. 2005;96:425-33.
68. Baker M, Vaughn D, Fanestil D. Inhibition by protease inhibitors of binding of adrenal and sex steroid hormones. J Supramol Struct. 1978;9:421-6.
69. Hubbard J, Kalimi M. Influence of protease inhibitors on glucocorticoid receptor properties: recent progress and future perspectives. Mol Cell Biochem. 1985;66:101-109.
70. Danoff A, Khan O, Wan D, et al. Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life. Am J Gastroenterol. 2006;101:1235-43.
71. Sollima S, Ossio M, Alciati A, et al. Protease inhibitors and male impotence. XIII IAC. Durban, South Africa, July 9-14, 2000 [abstract WePeB4216].
72. Mayo J, Collazos J, Martínez E Didanosine-induced ejaculatory dysfunction. Tenth International Conference on AIDS-International Conference on STD. Yokohama, Japan, August 7-12. 1994 [abstract PB0791].
73. Rogstad K, Shah R, Tesfaladet G, Abdullah M, Ahmed Jushuf I. Sexual dysfunction in patients with HIV infection and its association with autonomic neuropathy and CD4 count. 12th World AIDS Conference. Geneva. 1998 [abstract 32125].
74. Rosen R, Riley A, Wagner G, Osterloh I, Kirkpatrick J, Mishra A. The international index of erectile function: A multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822-30.
75. Weigel M, Meston C, Rosen R. The female sexual function index: cross-validation and development of clinical cut-off scores. J Sex Marital Ther. 2005;31:1-20.
76. Richardson D, Goldmeier D, Frize G, et al. Letrozole versus testosterone. A single-center pilot study of HIV-infected men who have sex with men on HAART with hypoactive sexual desire disorder and raised estradiol levels. J Sex Med. 2007;4:502-8.
77. Merry C, Barry M, Ryan M, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS. 1999;13:F101-7.
78. Muirhead G, Wulff M, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol. 2000;50:99-107.
79. Rosen R, Catania J, Ehrhardt A, et al. The Bolger conference on PDE-5 inhibition and HIV risk: implications for health policy and prevention. J Sex Med. 2006;3:960-75.